Multimodal 접근을 이미징 Bleomycin 유도 폐 섬유 증 생쥐에서의 경도 평가 대 한 마이크로-CT와 형광 분자 단층에 따라

Executive Industry Relevance

Non-invasive longitudinal imaging of lung fibrosis addresses a critical gap in preclinical IPF research by enabling repeated assessments without terminal procedures. This multimodal approach supports mechanistic de-risking by correlating molecular events with anatomical changes, improving predictive confidence in target validation. The method enhances translational continuity from discovery through preclinical evaluation, reducing late-stage biological risk in antifibrotic programs.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by tracking molecular events and anatomical progression in IPF-like models.
• Operational Value: Provides quantitative, reproducible readouts for pathway clarification and functional target validation.
• Strategic Value: Supports predictive confidence and portfolio triage through longitudinal disease severity monitoring.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for downstream workflows by establishing baseline fibrosis progression.
• Operational Value: Delivers standardized, quantitative imaging outputs suitable for assay reproducibility and scalability.
• Strategic Value: Enhances screening readiness by enabling reliable compound evaluation in longitudinal studies.

Translational & Preclinical Research

• Scientific Value: Aligns with disease relevance by modeling IPF pathogenesis through bleomycin-induced fibrosis.
• Operational Value: Ensures continuity from discovery through preclinical validation via repeated non-invasive imaging.
• Strategic Value: Informs risk-adjusted advancement decisions by providing longitudinal fibrosis quantification.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from Early Discovery to Lead Identification and Preclinical work by enabling hypothesis testing, pathway clarification, and quantitative disease monitoring.

• Discovery Biology: Supports hypothesis testing and pathway clarification by linking molecular events to anatomical changes in lung fibrosis.
• Screening: Provides assay readiness through reproducible, quantitative imaging of fibrosis progression over time.
• Analytics: Generates measurable outputs such as airway radius and fluorescence quantification to compare experimental conditions.
• Translational Research: Connects to preclinical continuity by enabling longitudinal monitoring that mirrors clinical disease progression.
• Enterprise Reuse: Functions as a reusable imaging platform for antifibrotic therapy evaluation across multiple study cycles.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence, target validation, reduction of mechanistic ambiguity in fibrosis mechanisms.
• Operational Value: Standardization, reproducibility, and scalability of non-invasive imaging across timepoints.
• Strategic Value: Better go/no-go decisions, capital efficiency, and reduced late-stage biological risk in IPF programs.
• Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on longitudinal fibrosis data.

Implementation Considerations

• Requires expertise in small animal imaging, anesthesia, and intravenous probe delivery.
• Depends on Micro-CT and FMT instrumentation with associated software for image acquisition and quantification.
• Necessitates cross-team standardization for consistent imaging protocols and data analysis.
• Involves adaptation considerations for different model systems and probe chemistries.
• Limited by the need for specialized equipment and operator training, as noted in the procedural workflow.

Biopharma FAQs